<DOC>
	<DOCNO>NCT02353754</DOCNO>
	<brief_summary>This Phase 4 , multicenter , open-label study evaluate EXPAREL infiltration transversus abdominis plane ( TAP ) bupivacaine hydrochloride ( HCl ) spinal anesthesia subject undergo elective Cesarean section ( C-section ) .</brief_summary>
	<brief_title>Evaluation Safety Efficacy EXPAREL When Administered Into TAP Subjects Undergoing Cesarean Section</brief_title>
	<detailed_description>There two group subject approximately 40 subject per group . Prior C-section , subject receive single-shot spinal anesthesia ( 1.5 mL bupivacaine HCl 0.75 % dextrose 8.25 % ) . Subjects Group 1 ( Standard Care ) receive intrathecal morphine injection ( e.g. , Duramorph® ) 0.2 mg conjunction single-shot spinal anesthesia . No TAP block administer . Subjects Group 2 ( EXPAREL/TAP ) receive bilateral TAP infiltration single 20 mL dose EXPAREL 266 mg expand volume 20 mL normal saline total volume 40 mL ( 20 mL infiltrated side abdomen ) .</detailed_description>
	<mesh_term>Bupivacaine</mesh_term>
	<mesh_term>Morphine</mesh_term>
	<criteria>1 . Females ≥18 year age screening . 2 . Scheduled undergo elective Csection ( single multiple birth ) . 3 . American Society Anesthesiology ( ASA ) physical status 1 , 2 , 3 . 4 . Able provide inform consent , adhere study visit schedule , complete study assessment . 1 . History hypersensitivity idiosyncratic reaction amidetype local anesthetic opioids . 2 . Contraindication bupivacaine , morphine , ketorolac , ibuprofen , acetaminophen . 3 . Planned concurrent surgical procedure exception salpingooophorectomy tubal ligation . 4 . Use following medication within time specify surgery : longacting opioid medication , nonsteroidal antiinflammatory drug ( NSAIDs ) , aspirin ( except lowdose aspirin use cardioprotection ) within 3 day , opioid medication acetaminophen within 24 hour . 5 . Initiation treatment follow medication within 1 month study drug administration medication ( ) give control pain : selective serotonin reuptake inhibitor ( SSRIs ) , selective norepinephrine reuptake inhibitor ( SNRIs ) , gabapentin , pregabalin ( Lyrica® ) , duloxetine ( Cymbalta® ) . If subject take one medication reason pain control , must stable dose least 1 month prior study drug administration . 6 . Clinically significant medical psychiatric disease , opinion Investigator , would constitute contraindication participation study cause inability comply study requirement . 7 . History , suspect , know addiction abuse illicit drug ( ) , prescription medication ( ) , alcohol within past 2 year . 8 . Received investigational drug within 30 day prior study drug administration , and/or plan administration another investigational product procedure participate study . 9 . Previous participate EXPAREL study . The subject withdrawn study meet follow criterion : 10 . Any clinically significant event condition uncover surgery ( e.g. , excessive bleeding , acute sepsis ) might render subject medically unstable complicate subject 's postsurgical course . 11 . Her baby 's 5minute Apgar score ≤7 .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>